

Title: Pulmonary radiological change of COVID-19 patients with ^{99m}Tc -MDP treatment

Authors: Xiaolin Yuan^{1#}, Ph.D., Wanrong Yi^{2#}, M.D., Baoyi Liu^{3#}, M.D., Simiao Tian³, Ph.D., Fang Cao³, Ph.D. student, Ruoyu Wang³, M.D., Baiwen Qi², M.D., Faqiang Lu³, M.D., Meiyun Fang⁴, M.D., Fuyang Pei⁵, M.D., Ming Chen², M.D., Lichuan Zhang⁵, M.D., Yong Zhang², M.D., Xiuzhi Zhang³, Ph.D., Zhenyu Pan², M.D., Dewei Zhao³, M.D., Aixi Yu², M.D.

Affiliations: ¹ Central laboratory, Affiliated Zhongshan Hospital of Dalian University, No. 6 Jiefang Street, Dalian, Liaoning, 116001, China

² Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China

³ Department of Orthopedics, Affiliated Zhongshan Hospital of Dalian University, No. 6 Jiefang Street, Dalian, Liaoning, 116001, China

⁴ Department of Rheumatology, Affiliated Zhongshan Hospital of Dalian University, No. 6 Jiefang Street, Dalian, Liaoning, 116001, China

⁵ Department of Respiratory Medicine, Affiliated Zhongshan Hospital of Dalian University, No. 6 Jiefang Street, Dalian, Liaoning, 116001, China

contributed equally.

***Corresponding author:** Dr. Dewei Zhao and Dr. Aixi Yu

Address correspondence to Dr. Dewei Zhao at Department of Orthopaedics, Affiliated Zhongshan Hospital of Dalian University, NO. 6 Jiefang Street Zhongshan District, Dalian, Liaoning Province, China, 116001. E-mail: Zhaodewei2016@163.com

Address correspondence to Dr. Aixi Yu at Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China. E-mail: yuaixi@whu.edu.cn

Abstract:

Background: As increasing cases of COVID-19 around world, urgent need for effective COVID-19-specific therapeutic drugs is necessary; therefore, we conducted a pilot randomized-controlled study to evaluate the efficacy of ^{99m}Tc -MDP for COVID-19 therapeutic treatment.

Methods: A total of 21 mild patients with COVID-19 were enrolled in this pilot RCT from February 2020 through March 2020, and then were assigned, in a 1:1 ratio, into control (11 patients) and ^{99m}Tc -MDP group (10 patients). Patients in the control group received routine treatment and patients assigned to the ^{99m}Tc -MDP group received a combination of routine treatment and an administration of ^{99m}Tc -MDP injection of 5ml/day. Both of the patients in the control and ^{99m}Tc -MDP groups were treated for 7 days with the primary end point of CT-based radiological pulmonary changes during 7-day follow-up.

Findings: From baseline to the day 7, 8 (80%) of 10 mild patients in the ^{99m}Tc -MDP group had a significant radiological improvement in lung and a decline in inflammatory infiltration, whereas only 1 (9.1%) of 11 patients in the control group had a radiological improvement in lung. None of the patients in the ^{99m}Tc -MDP group had disease progression from mild to severe, as well as an inflammatory cytokine storm, and 2 mild patients (18.2%) in the control group developed severe. During days 7 through 14, the number of patients with radiological improvement in the ^{99m}Tc -MDP group remained consistent, and only 1 additional case (22%) in the control group were reported.

Conclusion: In this randomized pilot study, ^{99m}Tc -MDP had an effective inhibitory effect on the inflammatory disease progression for the therapy of COVID-19, and it can accelerate the absorption of pulmonary inflammation in a short period of time during the process of treatment.

The recent outbreak of the novel coronavirus (2019-nCoV) is currently beginning spread to many countries around the world, and is becoming a pandemic according to World Health Organization (WHO).¹ The increasing cases and fatality highlight the urgent need for effective COVID-19-specific therapeutic drugs, which would prevent the progression of the disease, especially for decreasing the deterioration rate of respiratory and pulmonary infection. In the process of COVID-19, the cytokine storm is triggered by excessive inflammatory response and macrophage activation, which lead to multiple organ damages and even fatality; therefore, suppressing inflammatory response and targeting macrophage are both crucial for COVID-19 treatment. ^{99m}Tc-methylene diphosphonate (^{99m}Tc-MDP) is a first-in-class, highly active inhibitor of inflammation response and macrophage infiltration, and it is common drug therapy for use in autoimmune diseases such as rheumatoid arthritis with no significant adverse effects in clinical use.² In this pilot randomized controlled trial (RCT) study, ^{99m}Tc-MDP were administered in combination, with or without standard treatment for 7 days in patients with COVID-19. We report preliminary results from this exploratory cohort, with main focus of computed tomography (CT)-based radiological pulmonary changes at 7 days.

A total of 21 mild patients with COVID-19 were enrolled in this pilot RCT from February 2020 through March 2020 (Trial Registration: ChiCTR2000029431). Patients were considered eligible in this study on the basis of the WHO interim guidance³ and they were laboratory-confirmed positive on by the means of real-time reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay of nasal and pharyngeal swab specimens. Randomization was performed and ensured with the use of Web-based randomization system. Patients were assigned, in a 1:1 ratio, into control (11 patients) and ^{99m}Tc-MDP group (10 patients). Patients in the control group received routine treatment according to *Diagnostic of COVID-19* criteria issued by National Health Commission of China. Patients assigned to the ^{99m}Tc-MDP group received a combination of routine treatment and an administration of ^{99m}Tc-MDP injection of 5ml/day. Both of the patients in the control and ^{99m}Tc-MDP groups were

treated for 7 days. The primary end point was the CT-based radiological pulmonary changes from baseline to 7 days. The secondary end points were disease progression from mild to severe on the day 7, as well as radiological pulmonary changes during 7 days to 14 days after treatment.

Demographic characteristics were similar in the two groups except that patients in the control group were older than those in the ^{99m}Tc -MDP group (median age, 62 years vs. 57 years), there were fewer women in the control group than in the ^{99m}Tc -MDP group (55 % vs. 60%) (Table 1). On the day 7, 8 (80%) of 10 mild patients in the ^{99m}Tc -MDP group had a significant radiological improvement in lung and a decline in inflammatory infiltration, whereas only 1 (9.1%) of 11 patients in the control group had a radiological improvement in lung (Figure 1 and Figure S1 in the Supplementary Appendix). None of the patients in the ^{99m}Tc -MDP group had disease progression from mild to severe, as well as an inflammatory cytokine storm, and 2 mild patients (18.2%) in the control group developed severe. During days 7 through 14, the number of patients with radiological improvement in the ^{99m}Tc -MDP group remained consistent, and only 1 additional case (22%) in the control group were reported (Table 1).

In conclusion, in this randomized pilot study, the clinical drug, ^{99m}Tc -MDP had an effective inhibitory effect on the inflammatory disease progression from mild to severe for the therapy of COVID-19, and it can accelerate the absorption of pulmonary inflammation in a short period of time during the process of treatment. Besides, there were no serious adverse events including body immunity during the clinical use of ^{99m}Tc -MDP. Additional potential advantage for application of ^{99m}Tc -MDP is to avoid excessive use of glucocorticoids in the treatment of severe COVID-19 patients, in order to prevent further incidence of some glucocorticoids caused complications such as osteonecrosis of femoral head.⁴ Limited by the small sample size, larger and longer trials are warranted to determine the efficacy of ^{99m}Tc -MDP in the treatment of COVID-19.

References:

1. World Health Organization 2020.
(<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>).
2. Lai K, Xu L, Jin C, et al. Technetium-99 conjugated with methylene diphosphonate (99 Tc-MDP) inhibits experimental choroidal neovascularization in vivo and VEGF-induced cell migration and tube formation in vitro. *Invest Ophthalmol Vis Sci* 2011;52:5702-12.
3. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance. January 28, 2020
(<https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf>).
4. Zhao FC, Guo KJ, Li ZR. Osteonecrosis of the femoral head in SARS patients: seven years later. *Eur J Orthop Surg Traumatol* 2013;23:671-7.

Table1. Characteristics of the patients and End Points

	Total (N=21)	^{99m} Tc-MDP Group (N=10)	Control Group (N=11)	P value
Characteristics of the patients				
Age, median (IQR), y	61 (47-67)	57 (47-66)	62 (54-68)	0.417
Male sex - n (%)	9 (42.9%)	4 (40%)	5 (45%)	>0.99
End Points				
Patients with significant radiological pulmonary changes at day 7- n (%) of patients	9 (42.9%)	8 (80%)*	1 (9.1%)	0.002
Disease progression from mild to severe on the day 7 - n (%) of patients	2 (9.5%)	0 (0%)	2 (18.2%)	0.48
Patients with significant radiological pulmonary changes at day 14- n (%) of patients	10 (47.6%)	8 (80%)*	2 (22%)	0.009

IQR, interquartile range.

*P<0.05 between the ^{99m}Tc-MDP and control groups.

Figure 1: Computed Tomography (CT)-based radiographs of the patients' lung. On the top, shown are pulmonary radiographs for one patient in the ^{99m}Tc -MDP group at admission (A), at day 7 (B) and at day 14 (C); on the bottom, shown are pulmonary radiographs for one patient in control group at admission (D), at day 7 (E) and at day 14 (F).



